Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 717 of 6351
-
New pill aims to cut Parkinson's 'OFF' episodes in major trial
Disease control OngoingThis is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching pl…
Phase 3 • Sponsor: Cerevance • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Promising combo targets Hard-to-Treat childhood cancers
Disease control Recruiting nowStudy in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
Phase 1/2 • Sponsor: Fundación de investigación HM • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for advanced breast cancer patients who stopped responding to earlier therapies
Disease control Recruiting nowEvaluation of the efficacy of A166 in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with TOP1 inhibitor Antibody-Drug Conjugates
Phase 2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New Weight-Loss shot shows promise in major trial
Disease control CompletedThis is a multicenter, randomized, open, positive parallel controlled phase III clinical trial to compare the efficacy and safety of once-weekly HD1916 and semaglutide injection and to evaluate immunogenicity in obese non-diabetic adults.
Phase 3 • Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Tailor-Made T-Cells take on childhood brain cancer
Disease control Recruiting nowThis is an open-label phase 1 safety and feasibility study that will employ multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA) derived from a patient's primary brain tumor tissues. …
Phase 1 • Sponsor: Children's National Research Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a simple Self-Swab revolutionize cervical cancer screening?
Diagnosis CompletedThis study evaluates the performance of HPV testing on vaginal self-collected samples obtained with the Abbott Multi-Collect device. The study compares HPV test results from self-collected vaginal samples with results from clinician-collected cervical samples in women aged 30 to …
Sponsor: AML • Aim: Diagnosis
Last updated Aug 19, 2026 00:00 UTC
-
New hope for myelofibrosis patients: experimental drug RVU120 enters Mid-Stage trial
Disease control Recruiting nowThe objective of this clinical trial is to evaluate the efficacy (how well the drug works), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the study drug, RVU120, in treating adult patients with intermediate or high-risk, primary or secondary myelofibrosis. RVU120 wi…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New cell therapy trial hopes to tackle recurrent brain cancer
Disease control Recruiting nowThis study will enroll 6 DLT evaluable subjects (up to 12 patients total) where we will evaluate feasibility and safety of adoptive cellular therapy combined with IDH1/2 inhibitors in patients with recurrent or progressive oligodendroglioma WHO grade 2 and WHO grade 3.
Phase 1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug trial aims to slow rare Cancer's spread
Disease control Recruiting nowThis phase II trial tests how well zanzalintinib (XL092) works in treating patients with leiomyosarcoma that has spread from where it first started to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Leiomyosarcomas are a type sarcoma tha…
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New study tests best way to protect babies from RSV
Prevention CompletedRespiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants and young children. It is also a leading cause of mortality in children \<5 years of age worldwide. Until recently, no Food and Drug Administration (FDA)-approved vacci…
Phase 4 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Jun 27, 2026 12:32 UTC
-
New shot could ease droopy eyelids in rare muscle disease
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of efgartigimod PH20 SC given by a pre-filled syringe in adult patients with ocular myasthenia gravis. The study consists of a part A (approximately 7 weeks) and a part B (up to 2 years). In part A, half of the part…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Hit cancer early or wait? major trial tests timing of radiation for spread tumors
Disease control Recruiting nowThis protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (Trial 1), colorectal (Trial 2), and prost…
Phase 3 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New antibody drug targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New combo aims to make resistant prostate cancer vulnerable to radiation
Disease control Recruiting nowThis phase II trial tests how well vorinostat works in treating patients with prostate-specific membrane antigen (PSMA)-low castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) (mCRPC). Prostate c…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
AI listens for heart failure warning signs in your voice and cough
Diagnosis Recruiting nowHeart failure impacts more than 2% of people in the UK (United Kingdom) and leads to about 5% of emergency hospital visits. Patients might have slowly worsening symptoms or suddenly face acute decompensated heart failure (ADHF), marked by intense difficulty in breathing due to fa…
Sponsor: Cambridge University Hospitals NHS Foundation Trust • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
Light therapy shows promise for tough esophageal cancer cases
Disease control By invitation onlyThe objective of the present clinical trial is to assess the efficacy of photodynamic therapy (PDT) employing hematoporphyrin injection in the management of recurrent or residual superficial esophageal carcinoma. The principal objective is to determine the capability of this ther…
Phase 4 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Can a Two-Drug combo tame a rare blood cancer?
Disease control Recruiting nowThis is a phase 1/2 trial of pacritinib in combination with azacitidine in patients with Chronic Myelomonocytic Leukemia (CMML). Patients will be newly diagnosed or previously treated but could not have received a prior JAK inhibitor. Patients who have previously been treated wit…
Phase 1/2 • Sponsor: Douglas Tremblay • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a special dressing make skin grafts unnecessary for burns?
Symptom relief OngoingThe purpose of this study is to determine the effect to which Suprathel® (Polymedics Innovations GmbH, Denkendorf, Germany) can reduce the need for grafting compared to Standard of Care (SoC). Furthermore, the study intends to evaluate if Suprathel® allows for a reduction of redu…
Sponsor: The Metis Foundation • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Can pressurized oxygen heal Veterans' brain injuries? large trial launches
Symptom relief Recruiting nowThe goal of this blinded, adaptive, randomized, placebo-controlled clinical trial is to investigate the use of hyperbaric oxygen as a therapy to treat mild to moderate traumatic brain injury in Veterans and active military. The main questions it aims to answer are: * Does Hyperb…
Phase 3 • Sponsor: University of South Florida • Aim: Symptom relief
Last updated Jul 17, 2026 00:00 UTC
-
A simple wound rinse might cut Post-Surgery bleeding
Disease control Recruiting nowStudy objective: This is a study to investigate whether applying the drug tranexamic acid (TXA) onto a surgical wound surface may affect the incidence of surgical complications such as re-bleeding needing intervention, wound complications such as infection, wound rupture or sero…
Phase 4 • Sponsor: St. Olavs Hospital • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC